Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Bullish +65

Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business Fundamentals

📈 Novo Nordisk (NVO) is rated a BUY as business fundamentals outpace the current stock price.

💊 Oral Wegovy achieved over 3 million U.S. prescriptions in five months, with 80% from GLP-1-naïve patients.

🚀 Management raised 2026 guidance due to stronger-than-expected GLP-1 sales and international expansion.

🏥 Broader Medicare access is expanding the addressable market for Novo Nordisk's products.

📈 Analysts see continued upside toward a $75 price target based on accelerating growth.

🌍 International launches are proceeding rapidly, supporting long-term revenue diversification.

Bullish Signals
  • Novo Nordisk is rated a BUY because business fundamentals are recovering faster than the stock price.
  • Oral Wegovy has generated over 3 million U.S. prescriptions in just five months of launch.
  • 80% of oral Wegovy prescriptions come from GLP-1-naïve patients, indicating strong new market penetration.
  • Management raised 2026 guidance citing stronger-than-expected GLP-1 sales and international growth.
  • Broader Medicare access is expanding the company's addressable market significantly.
  • Accelerating international launches support continued upside toward a $75 price target.
Full Analysis
Novo Nordisk (NVO) is identified as a BUY opportunity because its business fundamentals are recovering faster than its current stock price, primarily driven by the historic U.S. launch of oral Wegovy. The article highlights that over 3 million prescriptions for oral Wegovy were filled in the U.S. within just five months, with an impressive 80% of these coming from patients who had not previously used GLP-1 medications. Management has officially raised its 2026 guidance, citing sales performance that exceeded expectations alongside robust international growth. The company's addressable market is expanding due to broader Medicare access and accelerating global launches, which supports a continued upside potential toward a $75 price target for the stock. The author notes this is their fourth analysis of NVO in eight months, focusing on early-commercial-stage life sciences companies. While the text includes standard author disclosures regarding a long position in NVO and Seeking Alpha's general disclaimers, the core financial thesis rests on the divergence between current valuation and accelerating revenue growth from new product launches.